Canaccord raised the firm’s price target on Exagen (XGN) to $7 from $5 and keeps a Buy rating on the shares. The firm previewed its coverage in the Diagnotstics and Tools universe for the year and it believes the outlook appears move favorable in 2025, albeit weighed toward the back end of the year. As the group underperformed in 2024 they acknowledege investors may be weary, but companies with possible meaningful product launches include Exagen could support a return to improved revenue growth.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.